Who buys Mylan stock?
MYL stock was sold by a variety of institutional investors in the last quarter, including Regent Investment Management LLC, Oakbrook Investments LLC, Meeder Asset Management Inc., Gofen & Glossberg LLC IL, Crossmark Global Holdings Inc., City Holding Co. and Whittier Trust Co.. View Insider Buying and Selling for Mylan.
How can I get the latest Mylan news and ratings?
Sign-up to receive the latest news and ratings for Mylan and its competitors with MarketBeat's FREE daily newsletter.
How has Mylan’s short interest decreased since 2016?
The most recent short interest data has been released for the 01/13/2017 settlement date, which shows a 2,159,951 share decrease in total short interest for Mylan NV (NASD: MYL), to 18,928,950, a decrease of 10.24% since 12/30/2016. Mylan’s price increases for EpiPen created a public firestorm.
Where can you buy MYL shares?
Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
See more
Is Mylan a public company?
In 1973, Mylan became a publicly traded company on the OTC market under the ticker symbol MYLN, and in 1976 moved to NASDAQ. Their final stock move was in 1986, when their stock became available for trade on the New York Stock Exchange under the ticker symbol MYL. Currently, the stock is traded on the NASDAQ.
When was Mylan acquired?
In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US. Mylan N.V.
What happens to Mylan stock after merger?
Upon completion of the Mylan Merger, Mylan ordinary shares will no longer be listed for trading on the NASDAQ, but Newco common stock will be listed on either the NASDAQ or the New York Stock Exchange under a ticker symbol to be determined.
Is Mylan owned by Pfizer?
Pfizer is planning to spin-out its generic drugs business into a joint venture with Mylan, in a deal that was due to be completed in the middle of the year. Now that the FTC has formally cleared the merger, the new firm, Viatris, will become a generics giant, with Pfizer owning 57% and Mylan owning 43%.
Is Mylan stock a Buy, Sell or Hold?
Mylan stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 2 hold ratings, and 0 sell ratings.
What was the 52-week low for Mylan stock?
For Mylan stock is no 52WeekLow data available or the value couldn't be calculated because of a value to close/at 0.00.
What was the 52-week high for Mylan stock?
For Mylan stock is no 52WeekHigh data available or the value couldn't be calculated because of a value to close/at 0.00.
What are analysts forecasts for Mylan stock?
The 2 analysts offering price forecasts for Mylan have a median target of 17.00, with a high estimate of 18.00 and a low estimate of 16.00. The med...
About Mylan
Headlines
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally.
What is Mylan NV?
Viatris Vs. Organon: Surprisingly Undervalued, But Which Is The Better Buy? - Seeking Alpha
Is Quantalytics a brokerage firm?
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World.
Is Pfizer a Mylan?
Quantalytics is not a registered investment adviser, brokerage firm, or investment company. Any data, information, or opinions presented by Quantalytics are for general information purposes only. Such data, information, or opinions are not an offer to sell or to buy, or a solicitation to buy or sell any securities.
Mylan (NASDAQ:MYL) Price Target and Consensus Rating
Pfizer (NYSE:PFE) today announced its plan to combine its generic drugs business with Mylan in a Reverse Morris Trust transaction. The combined entity could generate sales of over $20 billion by 2020, and Pfizer will hold a 57% stake in the new company, with Mylan holding the rest.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Mylan (NASDAQ:MYL) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
R.m.sincerbeaux Capital Management Llc Buys Viatris Inc, Boeing Co, Apple Inc, Sells ..
MarketBeat users like Mylan stock more than the stock of other Medical companies. 70.44% of MarketBeat users gave Mylan an outperform vote while medical companies recieve an average of 67.44% outperform votes by MarketBeat users.
Ar Asset Management Inc Buys Organon, Prometheus Biosciences Inc, Prometheus Biosciences Inc, ..
New York, NY, based Investment company R.m.sincerbeaux Capital Management Llc (Current Portfolio) buys Viatris Inc, Boeing Co, Apple Inc, Linde PLC, sells International Business Machines Corp, Kyndryl Holdings Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, R.m.sincerbeaux Capital Management Llc..
Monaco Asset Management SAM Buys Viatris Inc, TechnipFMC PLC, Barrick Gold Corp, Sells Antero ..
Beverly Hills, CA, based Investment company Ar Asset Management Inc (Current Portfolio) buys Organon, Prometheus Biosciences Inc, Prometheus Biosciences Inc, Church & Dwight Co Inc, sells AT&T Inc, Verizon Communications Inc, Marker Therapeutics Inc, Viatris Inc, Vimeo Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Ar Asset Management Inc..
Results
- Mylan NV (NASDAQ:MYL) posted its earnings results on Tuesday, May, 7th. The company reported $0.82 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.79 by $0.03. The business earned $2.50 billion during the quarter, compared to analyst estimates of $2.70 billion. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The company's …
Performance
- Mylan updated its FY19 earnings guidance on Tuesday, May, 7th. The company provided earnings per share guidance of $3.80-4.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.42. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.96 billion.
Risks
- 20 brokerages have issued 1 year target prices for Mylan's shares. Their predictions range from $22.00 to $59.00. On average, they expect Mylan's share price to reach $37.5263 in the next year. This suggests a possible upside of 69.3% from the stock's current price. View Analyst Price Targets for Mylan.
Ratings
- 20 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Mylan in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Mylan.
Reception
- Media headlines about MYL stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myla…
Ownership
- Mylan saw a decrease in short interest in the month of April. As of April 15th, there was short interest totalling 8,795,009 shares, a decrease of 26.4% from the March 29th total of 11,953,722 shares. Based on an average daily trading volume, of 4,054,263 shares, the short-interest ratio is presently 2.2 days. Approximately 1.7% of the shares of the company are sold short. View Mylan'…
Business
- Mylan has a market capitalization of $11.43 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe.